Clinical and Experimental Hypertension · 2001 · 13 citations · 19 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyMetabolic RegulationBlood Pressure ControlBlood Pressure ManagementDiabetes MellitusHypertension ControlHypertension ManagementHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive PharmacologyBeta-adrenergic Blocker UseBeta-adrenergic Receptor PharmacodynamicsBeta-blocker UseBlood PressureBlood Pressure PharmacodynamicsNonselective Beta-blocker Therapy
Bisoprolol, a beta1-selective beta-blocker, was administered to 13 patients with mild to moderate essential hypertension once daily at doses of 5-10 mg for 24 weeks, and its long-term effects on blood pressure and glucose metabolism were investigated. The systolic, diastolic and mean blood pressures were significantly reduced. At the end of the treatment period, the blood glucose level and hemoglobin A1c were not significantly different from those at baseline. In the glucose tolerance test at the end of the treatment period, the blood glucose and plasma insulin levels after a glucose load of 75 g were not significantly different at any time point, and the sums of each were not significantly different from their baseline levels. Based on these results, bisoprolol appears to be a beta1-selective beta-blocker possessing a satisfactory hypotensive effect without any adverse effects on glucose metabolism for long-term use, and is therefore a safe and useful drug for the treatment of essential hypertension.
19
Insulin Resistance in Essential Hypertension
Eleuterio Ferrannini, G. Buzzigoli, Riccardo C. Bonadonna et al. · New England Journal of Medicine · 1987 · 2.4K citations
Use of Propranolol (Inderal) in Treatment of Hypertension
B. N. C. Prichard, P. M. C. Gillam · BMJ · 1964 · 417 citations · Full text
Management of raised blood pressure in New Zealand: a discussion document.
Rod Jackson, Paul Barham, Janne Bills et al. · BMJ · 1993 · 265 citations · Full text